NEWSROOM
Press Releases by Agendia
News
Press Releases
Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics
Agreement Accelerates the Development of Tests to Help Assess Risk of Disease Recurrence in Women with Early-Stage Breast Cancer SANTA CLARA, Calif., IRVINE Calif., June 2, 2017-Agilent Technologies Inc. (NYSE: A) and Agendia, Inc. today Read More
Agendia’s MammaPrint Now Included in Blue Shield of California Coverage for Breast Cancer Patients
IRVINE, CA and AMSTERDAM – 1 June 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that Blue Shield of California has updated its Medical Policy 2.04.36 Assays Read More
Agendia’s MammaPrint Now Included in First Coast Coverage for Medicare Breast Cancer Patients in Florida, Puerto Rico and the Virgin Islands
IRVINE, CA and AMSTERDAM – 2 May 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that First Coast Service Options Inc. (“First Coast”), the Medicare contractor for Read More
Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman
IRVINE, CA and AMSTERDAM – 12 April 2017 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Read More
European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendia’s MammaPrint Test with Highest Level 1A Clinical Evidence
MammaPrint® is the first and only multigene test to receive level 1A status, based on prospective, randomized data from the MINDACT trial IRVINE, CA and AMSTERDAM, 21 March 2017 – Agendia, a world leader in Read More
German Gynecological Oncology Group (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence
2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer IRVINE, CA and AMSTERDAM – Read More
Agendia Co-Founder Laura van ‘t Veer Wins European Cancer Organization Clinical Research Award
Significant clinical benefit of Agendia’s MammaPrint® test and other advances in the improved treatment of breast cancer recognized at ceremony during ECCO2017 IRVINE, CA and AMSTERDAM – 30 January 2017 – Agendia, Inc., a world Read More